Cargando…
Risk Associated with Cumulative Oral Glucocorticoid Use in Patients with Giant Cell Arteritis in Real-World Databases from the USA and UK
INTRODUCTION: Treatment of giant cell arteritis (GCA) involves immediate initiation of high-dose glucocorticoid therapy with slow tapering of the dose over many months. Chronic exposure to glucocorticoids is associated with serious comorbidities. The objective of this analysis was to determine the g...
Autores principales: | Gale, Sara, Wilson, Jessica C., Chia, Jenny, Trinh, Huong, Tuckwell, Katie, Collinson, Neil, Dimonaco, Sophie, Jick, Susan, Meier, Christoph, Mohan, Shalini V., Sarsour, Khaled |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer Healthcare
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6251855/ https://www.ncbi.nlm.nih.gov/pubmed/29752705 http://dx.doi.org/10.1007/s40744-018-0112-8 |
Ejemplares similares
-
Adverse Events in Giant Cell Arteritis and Rheumatoid Arthritis Patient Populations: Analyses of Tocilizumab Clinical Trials and Claims Data
por: Gale, Sara, et al.
Publicado: (2019) -
Health-related quality of life in patients with giant cell arteritis treated with tocilizumab in a phase 3 randomised controlled trial
por: Strand, Vibeke, et al.
Publicado: (2019) -
Glucocorticoid Dosages and Acute‐Phase Reactant Levels at Giant Cell Arteritis Flare in a Randomized Trial of Tocilizumab
por: Stone, John H., et al.
Publicado: (2019) -
Impact of Glucocorticoid Cumulative Doses in a Real-Life Cohort of Patients Affected by Giant Cell Arteritis
por: Castan, Paul, et al.
Publicado: (2022) -
The effect of clinical features and glucocorticoids on biopsy findings in giant cell arteritis
por: Jakobsson, Karin, et al.
Publicado: (2016)